PrEParing for PrEP: From Policy to Implementation

PrEParing for PrEP: From Policy to Implementation

Registration Details

  • Virtual Preregistration: $35.00 (USD)
  • Virtual Preregistration ends: Friday, November 19, 2021


Susan P. Buchbinder, MD
University of California San Francisco
Jeffrey S. Crowley, MPH
Georgetown Law
Monica Gandhi, MD, MPH
University of California San Francisco
Marina Klein
Marina Klein, MD, MS
McGill University
Raphael J. Landovitz, MD
University of California Los Angeles
Henry Masur, MD
George Washington University School of Medicine
Jean-Michel Molina, MD
University of Paris
Michael S. Saag, MD
University of Alabama at Birmingham
Hyman Scott, MD, MPH
University of California San Francisco

November 19, 2021

11:00 AM - 4:00 PM ET

This course was initially planned as a hybrid activity, with a virtual component, and with a possible in-person component at the National Press Club in Washington, DC. We have decided that it is unsafe and impractical to have the in-person component of the PrEParing for PrEP: From Policy to Implementation. The course is now fully virtual. The course date will remain the same, and the updated agenda, including the updated course hours, is available on the activity page.

List of Topics

  • PrEP State of the Science
  • Optimizing PrEP
  • Assessing and Monitoring Those Starting and Continuing PrEP
  • The Impact of PrEP on Ending the HIV Epidemic
  • How to Reach the Hard to Reach
  • Leveraging Administrative and Governmental Policies to Improve PrEP Utilization

Last Modified: Nov 30, 2021 @ 9:12 AM

Program Description

This course will be an extensive review of utilizing preexposure prophylaxis to prevent HIV. Presenters will delve into the state-of-the-science of preexposure prophylaxis (PrEP) formulations and schedules, best practices for reaching those who would benefit from PrEP, as well as the governmental and administrative policies around PrEP.

Assessment of Needs

Rapid advances in HIV disease management require the ongoing attention of practitioners involved in HIV medicine. This course will address current state of the art in PrEP initiation and management, how PrEP can contribute to Ending the HIV Epidemic, and policies to address of preexposure prophylaxis (PrEP) to prevent HIV. Information will be presented through a mix of didactic lectures and panel discussions developed and led by an expert faculty of PrEP clinicians and researchers.

Learning Objectives

After participating in the activity, learners will be better able to:

  • Reflect on the most recent cutting edge data on PrEP
  • Describe the current state of the science in PrEP products, formulations, and schedules
  • Assess and monitor people interested in starting PrEP
  • Identify those who are getting PrEP and who are not but should
  • Describe the impact of PrEP on the Ending the HIV Epidemic initiative
  • Describe policies that could be improved to increase PrEP utilization

Conflicts of Interest

In the interest of maintaining the independence of its continuing education activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they or their spouses or partners have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing education activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA continuing education activity.

The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.


Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with or at risk for HIV infection and:

  • Have a solid, working knowledge of HIV
  • Provide comprehensive preventative care for patients at risk for HIV
  • Are currently active in PrEP research
  • Are interested in policies around PrEP barriers to access

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, other health professionals, and policy makers.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 8 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.

Continuing Education Credits

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Credits

Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.  Provider # 5-115.  This program is approved for 4.0 hours of continuing nursing education.

Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.

This program is approved for 4.0 hours of pharmacotherapy credit.

Pharmacy Credits

Accreditation Council for Pharmacy Education logo Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.   Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 4.0 contact hours (0.400 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event.  Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time.  The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN  # 0761-9999-21-258-L02-P

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.


Gilead Sciences, Inc.
Merck & Co., Inc.
ViiV Healthcare


Janssen Therapeutics


Theratechnologies Inc.

Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at or 415-544-9400.